(2) Oh C, Upmalis D, Okamoto A, Stegmann J. Flexible Use of Tapentadol Immediate Reelease for 90 Days for the Treatment of Low Back Pain and Osteoarthritis Pain: A Safety Study. Abstract FRI0335, 9th Annual European Congress of Rheumatology (EULAR 2008), 11-14 June 2008, Paris, France.
(3) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
(4) Rowbotham MC, Lindsey CD. How effective is long-term opioid therapy for chronic noncancer pain? Clin J Pain. 2007;23:300-2.
(5) McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127-35.
(6) Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125:172-.
(7) OPEN Minds. The white paper on opioids and pain: a pan-European challenge. 2005. Available from: http://www.openmindsonline.org/english/p... [Last accessed 09 Apr 2008].
(8) Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs. 2003;63:17-32.
(9) Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain 2008; 24: S8-S13.
(10) Oh C., Upmalis D., Okamoto A., Stegmann J. Tapentadol Immediate Release for 90 Days for the Treatment of Low Back Pain and Osteoarthritis Pain: A Safety Study. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA; Research and Development, Grunenthal GmbH, Aachen, Germany. Poster presented at the 9th Annual European Congress of Rheumatology (EULAR 2008), 11-14 June 2008, Paris, France.
Contact: Dr. Nicole Foellmer
Phone: +49-241-569-2858, Fax: +49-241-569-52858,
nicole.foellmer@grunenthal.com
Grunenthal GmbH, 52099 Aachen, Germany, http://www.grunenthal.com
Contact: Dr. Nicole Foellmer, Phone: +49-241-569-2858, Fax: +49-241-569-52858, nicole.foellmer@grunenthal.com
